—Is it asthma? Is it chronic obstructive pulmonary disease? In a genome-wide association study, researchers in the U.K. have determined signals that are associated with both diseases. Here are the ...

Chronic lower respiratory diseases, namely, asthma and chronic obstructive pulmonary disease (COPD), are the fifth-leading cause of death in the United States. A contributing factor is diagnostic ...

—According to findings of a large study of patient care in England and Wales, hospitalized patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma have different ...

Background: Asthma and COPD can significantly affect patients and pose a substantial economic burden for both patients and managed-care plans. This study compares utilization outcomes in patients with ...

Proton pump inhibitor (PPI) use in patients with chronic obstructive airway diseases is associated with an increased exacerbation risk.

Please provide your email address to receive an email when new articles are posted on . In a cohort of individuals with respiratory symptoms, 21% had undiagnosed COPD or asthma. Researchers found ...

Add Yahoo as a preferred source to see more of our stories on Google. Lead author Dr. Shawn Aaron, a senior scientist and lung specialist at The Ottawa Hospital in Ottawa, Ontario, Canada, described ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. COPD exacerbations went down by 51% in patients with ...

Adults receiving early-stage chronic obstructive pulmonary disease or asthma care from a pulmonologist had lower respiratory-related hospitalization and emergency department visit rates than those ...

Drugs already used by millions to lower cholesterol might someday have a new role: Relieving asthma and COPD. That's the hope of a new line of research underway at the University of California, Davis.

CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it described as a novel treatment a ...